Entasis Therapeutics Holdings Inc.

Entasis Therapeutics Holdings Inc.

ETTX

ETTXEntasis Therapeutics Holdings Inc. US flag

NASDAQ Global Market

2.19

USD

-0.01

- -

Entasis Therapeutics Holdings Inc.

ETTX

(NASDAQ Global Market)

Recent

price

2.19

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Orchard Therapeutics plc (ORTX)
Tricida, Inc. (TCDA)
Icosavax, Inc. (ICVX)
Unity Biotechnology, Inc. (UNBX)
Provention Bio, Inc. (PRVB)
Rocket Pharmaceuticals, Inc. (RCKT)
Business: Entasis Therapeutics Holdings Inc. Entasis Therapeutics Holdings Inc. (ETTX), a clinical-stage biopharmaceutical company and wholly owned subsidiary of Innoviva Inc., focuses on the discovery, development, and commercialization of targeted antibacterial products to treat serious infections caused by multidrug-resistant bacterial pathogens, particularly Gram-negative bacteria; its marketed products include GIAPREZA (angiotensin II) for septic shock and refractory hypotension, XERAVA (eravacycline) for complicated intra-abdominal infections, XACDURO (sulbactam for injection; durlobactam for injection) for hospital-acquired and ventilator-associated bacterial pneumonia and bloodstream infections caused by susceptible Acinetobacter baumannii, and ZEVTERA (ceftobiprole medocaril sodium for injection) for serious bacterial infections; the development pipeline features zoliflodacin, an oral antibiotic in Phase III trials for uncomplicated gonorrhea through collaboration with the Global Antibiotic Research and Development Partnership, ETX0282/CPDP in Phase I for urinary tract infections, ETX0462 in preclinical stages for multidrug-resistant Gram-negative infections, and additional candidates such as ETX1317 for Enterobacter infections. Founded in 2015 and headquartered in Waltham, Massachusetts, the company operates primarily in the United States with global partnerships including a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for durlobactam and SUL-DUR in Greater China. In 2022, Innoviva Inc. acquired all outstanding shares of Entasis it did not already own for $2.20 per share in cash, completing its transition to a fully owned subsidiary and advancing the commercialization of its precision-designed antibacterials addressing critical unmet needs in infectious disease treatment.

Company News